Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses.
about
Adenoviral vector immunity: its implications and circumvention strategies.HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach.Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsGene transfer into rat brain using adenoviral vectors.Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Adenoviral vector-mediated gene therapy for gliomas: coming of age.A titratable two-step transcriptional amplification strategy for targeted gene therapy based on ligand-induced intramolecular folding of a mutant human estrogen receptorGene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.Current progress in the development of a prophylactic vaccine for HIV-1.Prevention of diabetic neuropathy by regulatable expression of HSV-mediated erythropoietin.Current strategies and future directions for eluding adenoviral vector immunityQuantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.Functional analysis of Drosophila HSP70 promoter with different HSE numbers in human cellsOptimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.Conditionally replicating adenoviruses for cancer treatment.Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.Adenoviral-mediated gene transfer into the canine brain in vivo.Simultaneous live imaging of the transcription and nuclear position of specific genes.One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapsesImmune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactionsSafety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialHigh-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaTurning the gene tap off; implications of regulating gene expression for cancer therapeutics.Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma ModelRegulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators.Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors.Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivo.Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain.Progress in the development of genetic immunization.Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for gliomaTargeted gene therapy for the treatment of heart failure.Gene regulation systems for gene therapy applications in the central nervous system.Helper-Dependent Adenoviral Vectors and Their Use for Neuroscience Applications.Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors.Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine.
P2860
Q33565630-1D404675-8103-4A98-8A78-49D15759687CQ33646773-D8F2369C-2B35-4666-A7A5-D2F7E4FC5896Q33742711-C570B75E-9F82-4E9F-AE1E-30F56CED062EQ33877450-2A16FE23-4E2A-48A2-B1E8-D45E943E5143Q33904294-1C49E446-FF20-405B-AC82-7CAD05AA57D0Q33950709-529A71FE-0CB5-43F9-AD40-9D8FBBE2D5CAQ34012284-548616E1-79DF-4B4A-85DA-0E726AB79CDCQ34022048-866AD480-9585-475E-9877-3A1D8DC1A059Q34134386-5223A68B-324E-4010-BEA5-816BCBD710F1Q34359268-E259E1B1-EB28-4188-ABDC-C5D16826E6E1Q34502108-E71F1937-25BF-417C-A1B3-76BF19D777E1Q34556841-53839267-B174-4020-A313-C3E739DD6BAAQ34585554-2DED3739-BBEF-4D38-9A61-BA131B597566Q35069550-30A5752B-D3D4-45B1-9AAB-AE0AF8422DF0Q35118919-A91852E3-EA7D-4009-99DD-B184E7C85B55Q35220957-A2B39B74-5097-4823-8A5B-654FFFD844A5Q35870480-C82C14B4-1BCE-4CD5-A787-A40B674BAC4FQ35967313-2FBA2C9D-3C4E-40B2-A0CD-F1F021864EC6Q35999648-14946B6C-1F44-4E74-B15B-59A17832A808Q36172992-08AEB161-0D98-4EB2-80D9-3096D7DBA6BFQ36228002-11B02E0D-4C20-4CB1-BC67-0195EE5EF990Q36498762-6F87C562-B560-499D-8CFB-45FA9ACF63BCQ36498768-C637A755-650E-427B-B91F-1D7E84A7105AQ36498773-0943DE55-6F98-444F-BDC0-CA8D9082EC04Q36534329-84D8E474-D44A-4F49-B4B8-CBC4A88EEC43Q36540199-5566BE76-F2F2-4DE5-86E0-0FBC18BD0CCEQ36811505-61A99F0E-71C7-4F66-B7F1-CED03F0AAE9AQ36994041-F88C6419-3E1A-4B2B-9EB8-6BFD59A83DE3Q37050094-A39DB43D-B0B6-457B-9968-71B65A62F3D7Q37079181-15924D16-B0E1-49B3-AB40-FEFD4D92C1BBQ37089746-E4275425-69AF-4BFE-91DB-61AEC2EF23DAQ37099841-7200DC03-5E8F-4C5D-B1C0-FEA915D961DEQ37245006-3E2512E8-EEE0-4676-AB9E-942772D271EEQ37316018-495F3445-67EB-4FE6-8152-062B44EB6BB7Q37730116-27F426DF-E10E-474C-BE2F-0058197EBE14Q37878086-A52B1356-E3DC-49C8-B342-AD013EEF43C0Q37978318-2F020E06-0303-40AF-8856-2D4EFE272F17Q38436558-173C11A1-6B32-4129-B06C-DCF79FCFBD0EQ39737981-073706D8-3C43-4D11-905A-E756135DD874Q41699782-0F0382F4-0DB6-4FDF-AFC4-2858AB36C1B3
P2860
Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Regulatable gutless adenovirus ...... response against adenoviruses.
@ast
Regulatable gutless adenovirus ...... response against adenoviruses.
@en
Regulatable gutless adenovirus ...... response against adenoviruses.
@nl
type
label
Regulatable gutless adenovirus ...... response against adenoviruses.
@ast
Regulatable gutless adenovirus ...... response against adenoviruses.
@en
Regulatable gutless adenovirus ...... response against adenoviruses.
@nl
prefLabel
Regulatable gutless adenovirus ...... response against adenoviruses.
@ast
Regulatable gutless adenovirus ...... response against adenoviruses.
@en
Regulatable gutless adenovirus ...... response against adenoviruses.
@nl
P2093
P2860
P50
P1433
P1476
Regulatable gutless adenovirus ...... response against adenoviruses
@en
P2093
Chunyan Liu
Donna Palmer
Gabriela Jaita
Gwendalyn D King
Hasmik Agadjanian
Jeffrey M Zirger
Kurt Kroeger
Lali Medina-Kauwe
Marianela Candolfi
Pedro R Lowenstein
P2860
P356
10.1128/JVI.80.1.27-37.2006
P407
P577
2006-01-01T00:00:00Z